Carcinoid Syndrome Management Market, Global Outlook and Forecast 2022-2028

April 2022 | 64 pages | ID: C171CCCEC1BCEN
Market Monitor Global

Abstracts

Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor.

This report contains market size and forecasts of Carcinoid Syndrome Management in Global, including the following market information:

Global Carcinoid Syndrome Management Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Carcinoid Syndrome Management market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Carcinoid Syndrome Management include Novartis, Omega Laboratories, Teva Pharmaceutical, Mylan, Ipsen Biopharmaceuticals, Sirtex Medical, BTG International, Wockhardt and Sun Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Carcinoid Syndrome Management companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Carcinoid Syndrome Management Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Carcinoid Syndrome Management Market Segment Percentages, by Type, 2021 (%)

• Chemotherapy
• Biological Therapy
• Hepatic Artery Embolization Agents

Global Carcinoid Syndrome Management Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Carcinoid Syndrome Management Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Cancer Institute and Treatment Centers

Global Carcinoid Syndrome Management Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Carcinoid Syndrome Management Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Carcinoid Syndrome Management revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Carcinoid Syndrome Management revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novartis
• Omega Laboratories
• Teva Pharmaceutical
• Mylan
• Ipsen Biopharmaceuticals
• Sirtex Medical
• BTG International
• Wockhardt
• Sun Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Carcinoid Syndrome Management Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Carcinoid Syndrome Management Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CARCINOID SYNDROME MANAGEMENT OVERALL MARKET SIZE

2.1 Global Carcinoid Syndrome Management Market Size: 2021 VS 2028
2.2 Global Carcinoid Syndrome Management Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Carcinoid Syndrome Management Players in Global Market
3.2 Top Global Carcinoid Syndrome Management Companies Ranked by Revenue
3.3 Global Carcinoid Syndrome Management Revenue by Companies
3.4 Top 3 and Top 5 Carcinoid Syndrome Management Companies in Global Market, by Revenue in 2021
3.5 Global Companies Carcinoid Syndrome Management Product Type
3.6 Tier 1, Tier 2 and Tier 3 Carcinoid Syndrome Management Players in Global Market
  3.6.1 List of Global Tier 1 Carcinoid Syndrome Management Companies
  3.6.2 List of Global Tier 2 and Tier 3 Carcinoid Syndrome Management Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Carcinoid Syndrome Management Market Size Markets, 2021 & 2028
  4.1.2 Chemotherapy
  4.1.3 Biological Therapy
  4.1.4 Hepatic Artery Embolization Agents
4.2 By Type - Global Carcinoid Syndrome Management Revenue & Forecasts
  4.2.1 By Type - Global Carcinoid Syndrome Management Revenue, 2017-2022
  4.2.2 By Type - Global Carcinoid Syndrome Management Revenue, 2023-2028
  4.2.3 By Type - Global Carcinoid Syndrome Management Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Carcinoid Syndrome Management Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Cancer Institute and Treatment Centers
5.2 By Application - Global Carcinoid Syndrome Management Revenue & Forecasts
  5.2.1 By Application - Global Carcinoid Syndrome Management Revenue, 2017-2022
  5.2.2 By Application - Global Carcinoid Syndrome Management Revenue, 2023-2028
  5.2.3 By Application - Global Carcinoid Syndrome Management Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Carcinoid Syndrome Management Market Size, 2021 & 2028
6.2 By Region - Global Carcinoid Syndrome Management Revenue & Forecasts
  6.2.1 By Region - Global Carcinoid Syndrome Management Revenue, 2017-2022
  6.2.2 By Region - Global Carcinoid Syndrome Management Revenue, 2023-2028
  6.2.3 By Region - Global Carcinoid Syndrome Management Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Carcinoid Syndrome Management Revenue, 2017-2028
  6.3.2 US Carcinoid Syndrome Management Market Size, 2017-2028
  6.3.3 Canada Carcinoid Syndrome Management Market Size, 2017-2028
  6.3.4 Mexico Carcinoid Syndrome Management Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Carcinoid Syndrome Management Revenue, 2017-2028
  6.4.2 Germany Carcinoid Syndrome Management Market Size, 2017-2028
  6.4.3 France Carcinoid Syndrome Management Market Size, 2017-2028
  6.4.4 U.K. Carcinoid Syndrome Management Market Size, 2017-2028
  6.4.5 Italy Carcinoid Syndrome Management Market Size, 2017-2028
  6.4.6 Russia Carcinoid Syndrome Management Market Size, 2017-2028
  6.4.7 Nordic Countries Carcinoid Syndrome Management Market Size, 2017-2028
  6.4.8 Benelux Carcinoid Syndrome Management Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Carcinoid Syndrome Management Revenue, 2017-2028
  6.5.2 China Carcinoid Syndrome Management Market Size, 2017-2028
  6.5.3 Japan Carcinoid Syndrome Management Market Size, 2017-2028
  6.5.4 South Korea Carcinoid Syndrome Management Market Size, 2017-2028
  6.5.5 Southeast Asia Carcinoid Syndrome Management Market Size, 2017-2028
  6.5.6 India Carcinoid Syndrome Management Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Carcinoid Syndrome Management Revenue, 2017-2028
  6.6.2 Brazil Carcinoid Syndrome Management Market Size, 2017-2028
  6.6.3 Argentina Carcinoid Syndrome Management Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Carcinoid Syndrome Management Revenue, 2017-2028
  6.7.2 Turkey Carcinoid Syndrome Management Market Size, 2017-2028
  6.7.3 Israel Carcinoid Syndrome Management Market Size, 2017-2028
  6.7.4 Saudi Arabia Carcinoid Syndrome Management Market Size, 2017-2028
  6.7.5 UAE Carcinoid Syndrome Management Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis
  7.1.1 Novartis Corporate Summary
  7.1.2 Novartis Business Overview
  7.1.3 Novartis Carcinoid Syndrome Management Major Product Offerings
  7.1.4 Novartis Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.1.5 Novartis Key News
7.2 Omega Laboratories
  7.2.1 Omega Laboratories Corporate Summary
  7.2.2 Omega Laboratories Business Overview
  7.2.3 Omega Laboratories Carcinoid Syndrome Management Major Product Offerings
  7.2.4 Omega Laboratories Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.2.5 Omega Laboratories Key News
7.3 Teva Pharmaceutical
  7.3.1 Teva Pharmaceutical Corporate Summary
  7.3.2 Teva Pharmaceutical Business Overview
  7.3.3 Teva Pharmaceutical Carcinoid Syndrome Management Major Product Offerings
  7.3.4 Teva Pharmaceutical Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.3.5 Teva Pharmaceutical Key News
7.4 Mylan
  7.4.1 Mylan Corporate Summary
  7.4.2 Mylan Business Overview
  7.4.3 Mylan Carcinoid Syndrome Management Major Product Offerings
  7.4.4 Mylan Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.4.5 Mylan Key News
7.5 Ipsen Biopharmaceuticals
  7.5.1 Ipsen Biopharmaceuticals Corporate Summary
  7.5.2 Ipsen Biopharmaceuticals Business Overview
  7.5.3 Ipsen Biopharmaceuticals Carcinoid Syndrome Management Major Product Offerings
  7.5.4 Ipsen Biopharmaceuticals Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.5.5 Ipsen Biopharmaceuticals Key News
7.6 Sirtex Medical
  7.6.1 Sirtex Medical Corporate Summary
  7.6.2 Sirtex Medical Business Overview
  7.6.3 Sirtex Medical Carcinoid Syndrome Management Major Product Offerings
  7.6.4 Sirtex Medical Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.6.5 Sirtex Medical Key News
7.7 BTG International
  7.7.1 BTG International Corporate Summary
  7.7.2 BTG International Business Overview
  7.7.3 BTG International Carcinoid Syndrome Management Major Product Offerings
  7.7.4 BTG International Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.7.5 BTG International Key News
7.8 Wockhardt
  7.8.1 Wockhardt Corporate Summary
  7.8.2 Wockhardt Business Overview
  7.8.3 Wockhardt Carcinoid Syndrome Management Major Product Offerings
  7.8.4 Wockhardt Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.8.5 Wockhardt Key News
7.9 Sun Pharmaceutical
  7.9.1 Sun Pharmaceutical Corporate Summary
  7.9.2 Sun Pharmaceutical Business Overview
  7.9.3 Sun Pharmaceutical Carcinoid Syndrome Management Major Product Offerings
  7.9.4 Sun Pharmaceutical Carcinoid Syndrome Management Revenue in Global Market (2017-2022)
  7.9.5 Sun Pharmaceutical Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Carcinoid Syndrome Management Market Opportunities & Trends in Global Market
Table 2. Carcinoid Syndrome Management Market Drivers in Global Market
Table 3. Carcinoid Syndrome Management Market Restraints in Global Market
Table 4. Key Players of Carcinoid Syndrome Management in Global Market
Table 5. Top Carcinoid Syndrome Management Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Carcinoid Syndrome Management Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Carcinoid Syndrome Management Revenue Share by Companies, 2017-2022
Table 8. Global Companies Carcinoid Syndrome Management Product Type
Table 9. List of Global Tier 1 Carcinoid Syndrome Management Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Carcinoid Syndrome Management Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Carcinoid Syndrome Management Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Carcinoid Syndrome Management Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Carcinoid Syndrome Management Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Carcinoid Syndrome Management Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Carcinoid Syndrome Management Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Carcinoid Syndrome Management Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Carcinoid Syndrome Management Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Carcinoid Syndrome Management Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Carcinoid Syndrome Management Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Carcinoid Syndrome Management Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Carcinoid Syndrome Management Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Carcinoid Syndrome Management Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Carcinoid Syndrome Management Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Carcinoid Syndrome Management Revenue, (US$, Mn), 2023-2028
Table 30. Novartis Corporate Summary
Table 31. Novartis Carcinoid Syndrome Management Product Offerings
Table 32. Novartis Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 33. Omega Laboratories Corporate Summary
Table 34. Omega Laboratories Carcinoid Syndrome Management Product Offerings
Table 35. Omega Laboratories Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 36. Teva Pharmaceutical Corporate Summary
Table 37. Teva Pharmaceutical Carcinoid Syndrome Management Product Offerings
Table 38. Teva Pharmaceutical Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 39. Mylan Corporate Summary
Table 40. Mylan Carcinoid Syndrome Management Product Offerings
Table 41. Mylan Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 42. Ipsen Biopharmaceuticals Corporate Summary
Table 43. Ipsen Biopharmaceuticals Carcinoid Syndrome Management Product Offerings
Table 44. Ipsen Biopharmaceuticals Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 45. Sirtex Medical Corporate Summary
Table 46. Sirtex Medical Carcinoid Syndrome Management Product Offerings
Table 47. Sirtex Medical Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 48. BTG International Corporate Summary
Table 49. BTG International Carcinoid Syndrome Management Product Offerings
Table 50. BTG International Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 51. Wockhardt Corporate Summary
Table 52. Wockhardt Carcinoid Syndrome Management Product Offerings
Table 53. Wockhardt Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)
Table 54. Sun Pharmaceutical Corporate Summary
Table 55. Sun Pharmaceutical Carcinoid Syndrome Management Product Offerings
Table 56. Sun Pharmaceutical Carcinoid Syndrome Management Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Carcinoid Syndrome Management Segment by Type in 2021
Figure 2. Carcinoid Syndrome Management Segment by Application in 2021
Figure 3. Global Carcinoid Syndrome Management Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Carcinoid Syndrome Management Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Carcinoid Syndrome Management Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Carcinoid Syndrome Management Revenue in 2021
Figure 8. By Type - Global Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 9. By Application - Global Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 10. By Region - Global Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 11. By Country - North America Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 12. US Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 16. Germany Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 17. France Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 24. China Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 28. India Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 30. Brazil Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Carcinoid Syndrome Management Revenue Market Share, 2017-2028
Figure 33. Turkey Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Carcinoid Syndrome Management Revenue, (US$, Mn), 2017-2028
Figure 37. Novartis Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Omega Laboratories Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Teva Pharmaceutical Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Mylan Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Ipsen Biopharmaceuticals Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Sirtex Medical Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. BTG International Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Wockhardt Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Sun Pharmaceutical Carcinoid Syndrome Management Revenue Year Over Year Growth (US$, Mn) & (2017-2022)